Since FOXP3+ Tregs suppress the proliferation and function of CD8+ CTLs, and its strong infiltration associate with poor prognosis, it is understandable why CD8+ CTLs have not protective effect on survival of HER-2 positive cancer and only associate with better prognosis of HER-2 negative breast cancer. This evidence concerns the gene ERBB2 and cancer.